
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Outset Medical Inc (OM)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: OM (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -4.17% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.76M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 1411629 | Beta 2.01 | 52 Weeks Range 0.43 - 5.22 | Updated Date 02/18/2025 |
52 Weeks Range 0.43 - 5.22 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.74 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -122.84% | Operating Margin (TTM) -83.16% |
Management Effectiveness
Return on Assets (TTM) -26.83% | Return on Equity (TTM) -141.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 75213956 | Price to Sales(TTM) 0.42 |
Enterprise Value 75213956 | Price to Sales(TTM) 0.42 | ||
Enterprise Value to Revenue 0.66 | Enterprise Value to EBITDA -0.24 | Shares Outstanding 53703700 | Shares Floating 25533847 |
Shares Outstanding 53703700 | Shares Floating 25533847 | ||
Percent Insiders 2.22 | Percent Institutions 46.67 |
AI Summary
Outset Medical Inc. (NASDAQ: OTSM) - A Comprehensive Overview
Company Profile:
Detailed history and background:
Outset Medical Inc. was founded in 2008 with the mission to improve the lives of dialysis patients. The company started by developing and commercializing a portable hemodialysis system called Tablo, which aimed to provide patients with greater flexibility and independence compared to traditional in-center dialysis.
In 2020, Outset acquired NxStage Medical, a leading provider of home hemodialysis therapies. This acquisition solidified Outset's position as a leading player in the growing home hemodialysis market.
Description of the company's core business areas:
Outset Medical focuses on developing and commercializing innovative technologies for patients with chronic kidney disease (CKD). Their core business areas include:
- Home hemodialysis: Offering a suite of products and services for home dialysis, including the Tablo system, NxStage System One, and consumables.
- Dialysis supplies: Providing a range of consumables and accessories for in-center hemodialysis patients.
- Research and development: Investing in research to develop future technologies and improve existing products.
Overview of the company's leadership team and corporate structure:
Outset has a strong leadership team with extensive experience in the medical device industry. The key leadership positions include:
- Leslie Trigg, CEO: Over 20 years of experience in the healthcare industry, with expertise in launching innovative medical products.
- John Heuser, CFO: Extensive experience in finance and accounting, including leadership roles at publicly traded medical device companies.
- Dr. Joseph Vassalotti, Chief Medical Officer: Board-certified nephrologist with over 20 years of experience in clinical research and development.
Top Products and Market Share:
Identification and description of Outset Medical Inc's top products and offerings:
- Tablo Hemodialysis System: A portable hemodialysis system that allows patients to perform dialysis at home or other convenient locations.
- NxStage System One: A compact and user-friendly hemodialysis system designed for home use.
- Consumables: A range of disposable supplies for both Tablo and NxStage systems, including filters, tubing sets, and dialyzers.
Analysis of the market share of these products in the global and US markets:
- Tablo: holds a significant market share in the portable hemodialysis segment, particularly in the US.
- NxStage System One: has a leading position in the home hemodialysis market globally.
Comparison of product performance and market reception against competitors:
Outset's products are generally well-received by patients and clinicians, with high satisfaction ratings. The company's focus on innovation and user-friendliness has helped them gain a competitive edge in the market.
Total Addressable Market:
The global market for home hemodialysis is estimated to be around $5 billion and is expected to grow significantly in the coming years due to the increasing prevalence of CKD and the preference for home-based treatments.
Financial Performance:
Detailed analysis of recent financial statements:
Outset Medical has been experiencing strong revenue growth in recent years, driven by the adoption of its home hemodialysis products. The company is not yet profitable, but it is expected to reach profitability in the near future.
Year-over-year financial performance comparison:
Outset's revenue has grown consistently year-over-year, with a significant increase following the acquisition of NxStage. The company's operating expenses have also increased, but at a slower rate than revenue.
Examination of cash flow statements and balance sheet health:
Outset has a strong cash position and a healthy balance sheet. The company has sufficient cash reserves to fund its ongoing operations and growth initiatives.
Dividends and Shareholder Returns:
Outset Medical does not currently pay dividends. The company is focused on reinvesting its earnings to drive future growth.
Growth Trajectory:
Outset has a strong growth trajectory, driven by the increasing demand for home hemodialysis. The company is investing heavily in research and development to further expand its product portfolio and market reach.
Market Dynamics:
The home hemodialysis market is experiencing rapid growth due to several factors, including:
- Rising prevalence of chronic kidney disease: The number of people with CKD is increasing globally, driven by factors such as aging, diabetes, and obesity.
- Patient preference for home-based treatment: Home hemodialysis offers patients greater convenience and flexibility compared to in-center dialysis.
- Technological advancements: Advances in dialysis technology have made home hemodialysis more accessible and user-friendly.
Outset is well-positioned to benefit from these market dynamics, given its strong product portfolio and focus on innovation.
Competitors:
Outset's key competitors in the home hemodialysis market include:
- Fresenius Medical Care (NYSE: FME)
- Baxter International (NYSE: BAX)
- DaVita Inc. (NYSE: DVA)
Potential Challenges and Opportunities:
Key Challenges:
- Competition: The home hemodialysis market is becoming increasingly competitive, with major players investing heavily in new product development.
- Reimbursement: Reimbursement for home hemodialysis varies across different countries and healthcare systems, which can impact adoption rates.
- Patient education: Educating patients about the benefits of home hemodialysis and overcoming their concerns is crucial for market growth.
Potential Opportunities:
- Market expansion: The home hemodialysis market has significant growth potential, particularly in emerging markets.
- Product innovation: Outset is continuously developing new and improved products to expand its market reach and gain a competitive advantage.
- Strategic partnerships: Collaborating with other healthcare providers and organizations can help Outset expand its reach and improve patient care.
Recent Acquisitions:
Outset has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis, Outset Medical Inc. receives a fundamental rating of 7 out of 10. This rating is supported by the company's strong growth prospects, increasing market share, and healthy financial position. However, the company's lack of profitability and exposure to competition are factors that limit its overall rating.
Sources and Disclaimers:
This analysis is based on information available from Outset Medical Inc.'s website, financial reports, and other publicly available sources. The information provided should not be considered financial advice. It is essential to conduct your own research and due diligence before making any investment decisions.
About Outset Medical Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2020-09-15 | President, CEO & Chairman Ms. Leslie L. Trigg | ||
Sector Healthcare | Industry Medical Devices | Full time employees 480 | Website https://www.outsetmedical.com |
Full time employees 480 | Website https://www.outsetmedical.com |
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.